search
Back to results

Synthetic Cartilage Implant Versus Interposition Arthroplasty in Hallux Rigidus Treatment: A Randomized Clinical Trial

Primary Purpose

Hallux Rigidus

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Hallux Rigidus Treatment
Sponsored by
University of Iowa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hallux Rigidus

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Individuals must be older than 18 and younger than 75 years of age, both genders.
  • Participants must be experiencing symptoms related to their baseline condition for at least six months before the surgery.
  • Clinical and radiographical clinical diagnosis of hallux rigidus.
  • Hallux Rigidus grade III or grade IV.
  • Surgical indication after failure of nonoperative treatment (at least six months).

Exclusion Criteria:

  • Previous hallux metatarsophalangeal fusion.
  • Less than 20 degrees of complete range of motion on the hallux metatarsophalangeal joint.
  • Patient desire or medical indication for a hallux metatarsophalangeal joint arthrodesis.
  • Patient desire or medical indication for other surgical modalities.
  • History or documented evidence of autoimmune or peripheral vascular diseases.
  • History or documented evidence of peripheral neuropathy (nervous compression syndrome, tarsal tunnel syndrome) or systemic inflammatory disease a (rheumatoid arthritis, seronegative, connective, etc.).
  • Any condition that represents a contraindication of the proposed therapies.
  • Any physical or social limitation that makes the protocol continuation unviable.
  • Impossibility or incapacity to sign the informed Consent Form.
  • Presence of infectious process (superficial on the skin and cellular tissue, or deep in the bone) in the region to be treated.
  • Pregnancy.
  • Clinical and imaging diagnosis of untreated osteoporosis.
  • Serum vitamin D levels below 20ng/ml.
  • Non-palpable anterior or posterior tibial pulse; or abnormal capillary filling.
  • Tumor lesions (primary or secondary tumors).

Sites / Locations

  • University of Iowa Hospitals & ClinicsRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Synthetic Cartilage Implant

Dermal Interposition Arthroplasty

Arm Description

Outcomes

Primary Outcome Measures

Patient Reported Outcomes
To compare patient reported outcomes (PROs) of patients undergoing HR treatment using a synthetic implant and utilizing interposition arthroplasty.

Secondary Outcome Measures

Survival
To compare survival rate (reoperation) between the two techniques.
Complications
To compare major and minor complications between the two groups

Full Information

First Posted
August 25, 2022
Last Updated
September 29, 2022
Sponsor
University of Iowa
search

1. Study Identification

Unique Protocol Identification Number
NCT05518721
Brief Title
Synthetic Cartilage Implant Versus Interposition Arthroplasty in Hallux Rigidus Treatment: A Randomized Clinical Trial
Official Title
Synthetic Cartilage Implant Versus Interposition Arthroplasty in Hallux Rigidus Treatment: A Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 5, 2022 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Iowa

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A minimum of 100 patients with grade III hallux rigidus will be randomized in two parallel groups for surgical care. The first group will be submitted to the insertion of a synthetic cartilage implant at the metatarsophalangeal (MTP) joint. The second group will receive a dermal interposition arthroplasty at the MTP. Both sides will undergo the same post-operative protocol. Pain, complications, and functional results will be evaluated in a minimal of two years of follow-up.
Detailed Description
A minimum of 100 patients with grade III hallux rigidus will be randomized in two parallel groups for surgical care. The first group will be submitted to the insertion of a synthetic cartilage implant at the metatarsophalangeal (MTP) joint. The second group will receive a dermal interposition arthroplasty at the MTP. Both sides will undergo the same post-operative protocol. Pain, complications, and functional results will be evaluated in a minimal of two years of follow-up. The synthetic implant begins by performing and dorsal midline approach, from the proximal phalanx diaphysis to the first metatarsal neck. Dissection is carried avoiding injury to the dorsal cutaneous nerves and the extensor hallucis longus tendon. The capsule is open longitudinally, osteophytes removed, and a guidewire inserted through the center of the first metatarsal head. The position of the metallic wire is checked and the tunnel for the implant is drilled. The synthetic cartilage implant (Cartiva™, Stryker Medical®) is introduced through the tunnel, leaving it proud with the head surface by 2mm. The capsule is closed, followed by the other planes and the skin. The patient is banded and placed in a postoperative hard sole shoe for six weeks. Range of motion is encouraged from the third week and the shoe is discontinued after the sixth week. Return to sports activities and normal shoewear occurs by twelve weeks. The interposition arthroplasty initiates with the same dorsal midline approach, from the proximal phalanx diaphysis to the first metatarsal neck. Dissection is carried avoiding injury to the dorsal cutaneous nerves and the extensor hallucis longus tendon. The capsule is open longitudinally and osteophytes are removed. A guidewire inserted through the center of the first metatarsal head and the center of the proximal phalanx for proper surface preparation. Convex-concaves anatomical drills are used, removing remaining cartilage and opening space for the graft. A decellularized dermal allograft (Arthroflex™, Arthrex®) is placed at the joint and sutured to the head, maintaining the epidermal surface in contact with the phalanx. The graft is trimmed, the capsule is closed, which is followed by the other planes and the skin. The patient is banded and placed in a postoperative hard sole shoe for six weeks. Range of motion is encouraged from the third week and the shoe is discontinued after the sixth week. Return to sports activities and normal shoewear occurs by twelve weeks. The WBCT is the standard of care for the preoperative and postoperative assessment of patients with hallux rigidus. Some of the complications will also be evaluated through WBCT. No extra WBCT will be performed other than what we normally do for patients. Randomization will be performed previously at the beginning of the study and will be performed by an outside researcher. Allocation will happen during surgery scheduling.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hallux Rigidus

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Synthetic Cartilage Implant
Arm Type
Active Comparator
Arm Title
Dermal Interposition Arthroplasty
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Hallux Rigidus Treatment
Intervention Description
Participants will receive either a synthetic cartilage implant or dermal interposition arthroplasty
Primary Outcome Measure Information:
Title
Patient Reported Outcomes
Description
To compare patient reported outcomes (PROs) of patients undergoing HR treatment using a synthetic implant and utilizing interposition arthroplasty.
Time Frame
96 weeks post-surgery
Secondary Outcome Measure Information:
Title
Survival
Description
To compare survival rate (reoperation) between the two techniques.
Time Frame
6 months post-surgery
Title
Complications
Description
To compare major and minor complications between the two groups
Time Frame
6 months post-surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Individuals must be older than 18 and younger than 75 years of age, both genders. Participants must be experiencing symptoms related to their baseline condition for at least six months before the surgery. Clinical and radiographical clinical diagnosis of hallux rigidus. Hallux Rigidus grade III or grade IV. Surgical indication after failure of nonoperative treatment (at least six months). Exclusion Criteria: Previous hallux metatarsophalangeal fusion. Less than 20 degrees of complete range of motion on the hallux metatarsophalangeal joint. Patient desire or medical indication for a hallux metatarsophalangeal joint arthrodesis. Patient desire or medical indication for other surgical modalities. History or documented evidence of autoimmune or peripheral vascular diseases. History or documented evidence of peripheral neuropathy (nervous compression syndrome, tarsal tunnel syndrome) or systemic inflammatory disease a (rheumatoid arthritis, seronegative, connective, etc.). Any condition that represents a contraindication of the proposed therapies. Any physical or social limitation that makes the protocol continuation unviable. Impossibility or incapacity to sign the informed Consent Form. Presence of infectious process (superficial on the skin and cellular tissue, or deep in the bone) in the region to be treated. Pregnancy. Clinical and imaging diagnosis of untreated osteoporosis. Serum vitamin D levels below 20ng/ml. Non-palpable anterior or posterior tibial pulse; or abnormal capillary filling. Tumor lesions (primary or secondary tumors).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cesar De Cesar Netto, MD
Phone
(319) 678-7943
Email
cesar-netto@uiowa.edu
Facility Information:
Facility Name
University of Iowa Hospitals & Clinics
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cesar de Cesar Netto

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Synthetic Cartilage Implant Versus Interposition Arthroplasty in Hallux Rigidus Treatment: A Randomized Clinical Trial

We'll reach out to this number within 24 hrs